| |
Serum bcl-2 antigen (ELISA) |
|
| |
Total No. (%) |
Positive bcl-2 No. (%) |
Negative bcl-2 No. (%) |
P. value |
| Mean Age ± SD |
49.9 ± 2.96 |
48.5 ± 12.8 |
50.6 ± 13.4 |
0.88 |
| Sex |
|
0.1 |
| Male |
29 (64.4%) |
6 (20.7%) |
23 (79.3%) |
| Female |
16 (35.6%) |
7 (43.7%) |
9 (56.3%) |
| Size |
|
0.19 |
| <5 |
17 (37.8%) |
3 (17.6%) |
14 (82.4%) |
| >5 |
28 (62.2%) |
10 (35.7%) |
18 (64.3%) |
| Site |
|
0.17 |
| Antrum |
25 (55.6%) |
8 (32.0%) |
17 (68.0%) |
| Body |
13 (28.9%) |
4 (30.8%) |
9 (69.2%) |
| Cardia |
7 (15.6%) |
1 (14.3%) |
6 (85.7%) |
| Gross (shape) |
|
0.19 |
| Ulcerating |
27 (60.0%) |
8 (32.0%) |
19 (70.4%) |
| Infiltrating |
9 (20.0%) |
4 (30.8%) |
8 (88.9%) |
| Polypoi |
9 (20.0%) |
1 (14.3%) |
5 (55.6%) |
| Type |
|
|
|
0.8 |
| Epithelial tumor |
37 (82.2%) |
8 (29.6%) |
27 (73.0%) |
| Stromal tumor |
3 (06.7%) |
1 (11.1%) |
1 (33.3%) |
| NHL |
5 (11.1%) |
4 (44.4%) |
4 (40.0%) |
| Grade |
|
0.12 |
| Low |
10 (22.2%) |
3 (30.0%) |
7 (70.0%) |
| Intermediate |
23 (51.1%) |
4 (17.4%) |
19 (82.6%) |
| High |
12 (26.7%) |
6 (50.0%) |
6 (50.0%) |
| Total |
45 (100%) |
13 (28.9%) |
32 (71.1%) |
|
|
